基于材料和细胞的技术，如工程组织，作为人类疗法具有巨大的潜力。然而，由于体内移植实验的繁琐和低通量性质，在许多这些技术的开发阶段停滞不前，仅限于临床前动物研究阶段。我们介绍了一种名为高度并行组织移植（HPTG）的“即插即用”体内筛选阵列平台。 HPTG使43个三维微小组织在单个3D打印设备内进行并行化体内筛选。使用HPTG，我们筛选具有不同细胞和材料组分的微小组织形成，并确定支持血管自组装，整合和组织功能的组成配方。我们的研究强调了同时改变细胞和材料配方变量的组合研究的重要性，通过揭示包括基质细胞可“拯救”依赖于材料的血管自组装的方式。 HPTG为加速组织疗法，癌症生物医学和再生医学等多种医学应用的临床前进展提供了途径。

Material- and cell-based technologies such as engineered tissues hold great promise as human therapies. Yet, the development of many of these technologies becomes stalled at the stage of pre-clinical animal studies due to the tedious and low-throughput nature of in vivo implantation experiments. We introduce a 'plug and play' in vivo screening array platform called Highly Parallel Tissue Grafting (HPTG). HPTG enables parallelized in vivo screening of 43 three-dimensional microtissues within a single 3D printed device. Using HPTG, we screen microtissue formations with varying cellular and material components and identify formulations that support vascular self-assembly, integration and tissue function. Our studies highlight the importance of combinatorial studies that vary cellular and material formulation variables concomitantly, by revealing that inclusion of stromal cells can "rescue" vascular self-assembly in manner that is material-dependent. HPTG provides a route for accelerating pre-clinical progress for diverse medical applications including tissue therapy, cancer biomedicine, and regenerative medicine.